• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glenmark, Evestra ink deal to develop generic NuvaRing

March 2, 2017 By Sarah Faulkner

Glenmark, Evestra ink deal to develop generic NuvaRingGlenmark Pharmaceuticals and Evestra said today that the companies inked a development, license and commercialization deal for a generic version of Merck’s NuvaRing.

Development of the etonogestrel/ethinyl estradiol contraceptive is under way, according to the companies, and they plan to file an Abbreviated New Drug Application in fiscal 2019.

“This is an important U.S.-based strategic partnership for Evestra,” president & CEO Ze’ev Shaked said in prepared remarks. “By aligning our efforts, we expect to make great strides in improving women’s healthcare and access to options that are significantly more accessible due to their lower costs. We are excited to work with Glenmark.”

San Antonio-based Evestra said it will develop the product exclusively for Glenmark within the U.S. market and is slated to receive milestone payments contingent upon the vaginal ring’s development. Evestra is also eligible to receive royalties on net sales.

“Bringing high-quality and affordable options to market has been a core commitment for Glenmark since the beginning,” president of U.S. and global API biz Robert Matsuk added. “The partnership with Evestra underscores that focus, and expands our portfolio into a leading non-daily contraceptive option prescribed to millions of women in the U.S.”

Merck’s NuvaRing brought in sales of $768 million in 2016 within the U.S., the companies reported. The small, flexible ring releases a continuous low dose of hormones for 3 weeks at a time.

Research has shown that when used as directed, the NuvaRing is just as effective as a daily, oral contraceptive.

Filed Under: Featured, Research & Development, Wall Street Beat, Women's Health Tagged With: Evestra, Glenmark Pharmaceuticals

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS